XML 72 R35.htm IDEA: XBRL DOCUMENT v3.22.0.1
Disposition of the Hospital Business - (Tables)
 12 Months Ended
Dec. 31, 2021
Discontinued Operations and Disposal Groups [Abstract]  
Schedule of Assets and Liabilities either Transferred Or Eliminated Representing the Aggregate Consideration of Disposal Group The $45,760 gain represents the aggregate consideration of $42,000, less transaction fees of $2,928, plus the assets and liabilities either transferred to the Exela Buyer or eliminated by the Company due to the sale of the Hospital Products, which are listed below.
June 30, 2020
Prepaid expenses and other current assets$(134)
Inventories(4,922)
Goodwill(1,654)
Intangible assets, net(407)
Other non-current assets(1,095)
Total long-term contingent consideration payable14,900 
Net liabilities disposed of6,688 
Aggregate consideration42,000 
Less transaction fees(2,928)
Net gain on the sale of the Hospital Products$45,760 
Schedule of Error Corrections and Prior Period Adjustments
The unaudited pro forma condensed combined statements of (loss) income for the years ended December 31, 2020 and 2019 included below is being provided for information purposes only and are not necessarily indicative of the results of operations that would have resulted if the Transaction had actually occurred on the date indicated. The pro forma adjustments are based on available information and assumptions that the Company believes are attributable to the sale.

Unaudited Pro Forma Condensed Combined Statement of (Loss) Income
Year Ended December 31, 2020
 As ReportedPro Forma AdjustmentsNotesPro Forma
Product sales$22,334 $(22,175)(a)$159 
Total operating expense16,519 (8,392)(b)8,127 
Operating income (loss)5,815 (13,783)(7,968)
Loss before income taxes$(5,082)$(13,348)(c)$(18,430)

Unaudited Pro Forma Condensed Combined Statement of (Loss) Income
Year Ended December 31, 2019
 As ReportedPro Forma AdjustmentsNotesPro Forma
Product sales$59,215 $(59,273)(a)$(58)
Total operating expense83,327 (16,092)(d)67,235 
Operating loss(24,112)(43,181)(67,293)
Loss before income taxes$(38,582)$(42,803)(e)$(81,385)

Adjustments to the pro forma unaudited condensed combined statements of (loss) income

(a) This adjustment reflects Product sales attributable to the Hospital Products.

(b) This adjustment reflects the following estimated expenses attributable to the Hospital Products:

•Cost of products of $3,540.
•R&D expenses of $322.
•Selling, general and administrative expenses of $797.
•Intangible asset amortization on acquired development technology for Vazculep of $406.
•Changes in fair value of related party contingent consideration of $3,327. The Company will no longer be responsible for these payments.

(c) This amount reflects the adjustments noted in (a) and (b) above, as well as estimated Changes in fair value of related party payable of $435 attributable to the Hospital Products. The Company will no longer be responsible for these payments.

(d) This adjustment reflects the following estimated expenses attributable to the Hospital Products:

•Cost of products of $11,368.
•R&D expenses of $1,960.
•Selling, general and administrative expenses of $1,102.
•Intangible asset amortization on acquired development technology for Vazculep of $816.
•Changes in fair value of related party contingent consideration of $845. The Company will no longer be responsible for these payments.

(e) This amount reflects the adjustments noted in (a) and (d) above, as well as the reversal of estimated Changes in fair value of related party payable of $378 attributable to the Hospital Products. The Company will no longer be responsible for these payments.